China has been engaged in the R&D and manufacturing of semi-automatic coagulation analyzers for over a decade, and based on the data from the website of the NMPA, in 2024 and 2025 (as od 15 August), a total of 2 instruments from 2 manufacturers have obtained registration certificates...

Stay up-to-date with the latest happenings in the rapidly evolving field of In Vitro Diagnostics (IVD) in China. Latest news

Jabil Inc. is consolidating its healthcare businesses under Jabil Healthcare. These include Jabil’s embedded-sensors business, its injection molding business through Nypro, and its orthopedics, spine, trauma, and medical instruments operat

Researchers from Linköping University are behind a new study that has used artificial intelligence to investigate whether it is possible to discover biological networks using deep learning, in which entities known as "artificial neural netw

Abbott Laboratories has won CE mark for the new Gallant implantable cardioverter-defibrillator (ICD) and CRT-D devices. The Abbott Park, Il-based company received approval in Europe on the heels of ICD Week, a celebration of 40 years of the

Ares Genetics, a Curetis Group company, will collaborate with BGI Group to make molecular tests for coronavirus 2019-nCoV available in Europe.

China has been a large and ever-expanding market for Roche, driving much of the company's international growth, and this week, the firm said several initiatives and developments in that country keep it a crucial strategic market for its diag

Abcam said on Thursday that it has acquired the gene editing platform and oncology product portfolio of Applied StemCell for the research and diagnostic markets.

The US Food and Drug Administration late on Tuesday issued an emergency use authorization for a test from the US Centers for Disease Control and Prevention for the novel coronavirus, 2019-nCoV.

Roche on Thursday reported a 3 percent increase in sales of its diagnostics division in 2019, driven primarily by its immunodiagnostic solutions, which are part of its Centralized and Point of Care Solutions business.

Danaher reported on Thursday a 6 percent year-over-year increase in total sales for the fourth quarter, beating the consensus Wall Street estimate.

AnPac Bio-Medical Science said on Thursday that it has priced its initial public offering of roughly 1.3 million American depositary shares (ADS) at $12 apiece, for total proceeds of around $16.0 million.